CIK 0001497253
- Non-accelerated filer
- Smaller reporting company
VivoSim Labs, INC.
Sign in to watch- Ticker
- VIVS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 271488943
- Phone
- +1 858-224-1000
- Business address
- 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121
- Former names
- ORGANOVO HOLDINGS, INC., REAL ESTATE RESTORATION & RENTAL, INC.
- Open-market buys, last 90 days
- $2,804
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$2,804. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-07-11 | Bush Jennifer General Counsel & Secretary | Grant or award | +50,000 | 50,000 | ||
| 2016-07-11 | Bush Jennifer General Counsel & Secretary | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2016-02-16 | Murphy Keith Chairman, CEO and President | Shares withheld for taxes | −24,690 | $2.04 | $50K | 5,919,638 |
| 2016-02-16 | Murphy Keith Chairman, CEO and President | Grant or award · Stock Option (Right to Buy) | +24,690 | 24,690 | ||
| 2015-09-21 | Baltera Robert Jr. Director | Sale | −6,000 | $4.03 | $24K | 138,506 |
| 2015-08-24 | MICHAELS BARRY D Chief Financial Officer | Shares withheld for taxes | −100,692 | $2.32 | $234K | 86,808 |
| 2015-08-24 | MICHAELS BARRY D Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +100,692 | 100,692 | ||
| 2015-08-20 | Malloy Kirk Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2015-08-20 | HOWSON TAMAR D Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2015-08-20 | Heyman Richard A. Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2015-08-20 | GLOVER JAMES T Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2015-08-20 | Baltera Robert Jr. Director | Grant or award · Stock Option (Right to Buy) | +37,000 | 37,000 | ||
| 2015-08-20 | Gallant Paul General Manager | Grant or award · Stock Option (Right to Buy) | +225,000 | 225,000 | ||
| 2015-08-13 | GLOVER JAMES T Director | Purchase | +10,000 | $2.80 | $28K | 10,000 |
| 2015-08-12 | Murphy Keith Chairman, CEO and President | Purchase | +20,000 | $2.56 | $51K | 5,944,328 |
| 2015-06-04 | Renard Michael EVP of Commercial Operations | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2015-06-04 | Presnell Sharon Collins EVP, Research & Dev & CTO | Grant or award · Stock Option (Right to Buy) | +130,000 | 130,000 | ||
| 2015-06-04 | Murphy Keith Chairman, CEO and President | Grant or award · Stock Option (Right to Buy) | +465,000 | 465,000 | ||
| 2015-06-04 | MICHAELS BARRY D Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +255,000 | 255,000 | ||
| 2015-06-04 | David Eric CSO & EVP Pre-Clinical Dev | Grant or award · Stock Option (Rignt to Buy) | +130,000 | 130,000 |
Page 12 of 13 · 259 trades